Download - TERAPI SISTEMIK KANKER PAYUDARA
![Page 1: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/1.jpg)
TERAPI SISTEMIK KANKER PAYUDARA
Dr. I MD DUWI SUMOHADI SpPD KHOM FINASIM
RS BALIMED 2021
![Page 2: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/2.jpg)
INTRODUCE:
Incidence and
mortality; 2012
GLOBOCAN DATABASE
2012-WORLD:
Breast cancer remain the
second most common
cause of cancer,
estimated 1,67 million new
cancer case diagnosed in
2012.
Females: Breast, colo-
rectal and cervix cancer.
INSIDENCE AND MORTALITY BREAST CANCER 2012
![Page 3: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/3.jpg)
Breast cancer
statistic in
American
Breast cancer accounting
25% of all cancer.
In USA (2013): new breast
cancer was estimated at
232.340 and the number
of death at 39.620.
Incidence rate ranging
from 27 per 100.000 in
middle Africa and Eastern
Asia.
![Page 4: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/4.jpg)
GLOBOCAN DATABASE 2020; Estimated new case breast cancer in 2020
![Page 5: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/5.jpg)
INSIDEN DI INDONESIA: RISKESDAS 2019
◦ Insiden kanker di Indonesia:
136,2/100.000 penduduk.
◦ Peringkat 8 di Asia Tenggara
◦ Peringkat 23 di Asia
◦ Pada Wanita: kanker payudara
terbanyak: insiden 42,1/100.000
penduduk.
◦ Angka kematian: 17 per 100.000
penduduk.
![Page 6: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/6.jpg)
Hereditary (10% of patients have first degree relatives).
Genetic mutations: BRCA1 and BRCA2.
Radiation: history mantle radiotherapy during childhood (R/ LimfomaHodgkin)
Hormonal factors: HRT (hormonal replacement treatment contain estrogen and progesterone)
ETIOLOGY OF
BREAST
CANCER
![Page 7: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/7.jpg)
PATHOLOGY:
◦ Carcinomas in situ: ductal carcinoma in situ (DCIS), Lobuler carcinoma in situ (LCIS)
◦ Invasive carcinomas:
◦ Invasive ductal carcinoma (80%)
◦ Invasive lobular carcinoma (10%)
◦ Other invasive carcinoma: Medullary, papillary, tubular, cribriform, metaplastic,
squamus, adenoid cystic, mucinous, secretory, and undifferentiated.
![Page 8: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/8.jpg)
Subtype of
Breast cancer
![Page 9: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/9.jpg)
SYMPTOM OF BREAST CANCER
![Page 10: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/10.jpg)
TNM STAGING
FOR BREAST
CANCER AJCC 7th
AJCC: American joint
committee on cancer:
TNM staging
![Page 11: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/11.jpg)
TNM STAGING
FOR BREAST
CANCER AJCC 7th
N: Nodal
![Page 12: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/12.jpg)
TNM STAGING
FOR BREAST
CANCER AJCC 7th
M: metastasis
![Page 13: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/13.jpg)
![Page 14: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/14.jpg)
STAGING OF
BREAST CANCERSTAGING OF BREAST CANCER (TNM)
![Page 15: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/15.jpg)
TREATMENT IN BREAST CANCER:
![Page 16: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/16.jpg)
BREAST CANCER IN INDONESIA:
◦ Coming to hospital: with advance stage or metastasis.
◦ History with alternatif treatment: infection ???
◦ screening program???
![Page 17: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/17.jpg)
THERAPY OF
BREAST CANCER
Early stage goals of therapy is cure
![Page 18: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/18.jpg)
THERAPY OF BREAST CANCER:
![Page 19: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/19.jpg)
Systemic therapy for breast cancer
◦ Systemic therapy:
Hormonal therapy
Chemotherapy (Neo-adjuvant or Adjuvant)
Targeted therapy
Immune therapy
Biological therapy
![Page 20: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/20.jpg)
Systemic therapy for breast cancer
◦ Neoadjuvant systemic therapy: considered in patients with locally advance
breast cancer, because tumor regression increase the opportunities for breast
conserving treatment (BCT).
◦ Adjuvant systemic therapy: addresses the possibility of occult micro-metastasis,
which can, with time grow into overt metastasis disease.
![Page 21: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/21.jpg)
Systemic therapy for breast cancer
◦ Neoadjuvant and Adjuvant systemic therapy:
◦ HORMONAL THERAPY OR CHEMOTHERAPY
◦ Targeting therapy (anti-HER2)
![Page 22: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/22.jpg)
INDICATION THERAPY:
◦ NEO-ADJUVANT OR ADJUVANT SYSTEMIC THERAPY: HORMONAL?? CHEMOTHERAPY??
TARGETED THERAPY?? OR THE OTHERS??
◦ GUIDELINES: NCCN…
◦ Based on: staging tumour, hormonal status and HER/EGFR (Epidermal growth factors receptor) status.
◦ Hormonal status: ER/PR
◦ HER : HER1,2,3 or 4
![Page 23: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/23.jpg)
![Page 24: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/24.jpg)
NCCN Guidelines (2016)
Invasive Breast
Cancer:
Systemic adjuvant
Hormonal therapy:
Hormone receptor positive
(HR +)
Systemic adjuvant treatment: hormone receptor and HER2 positive
![Page 25: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/25.jpg)
HORMONAL AGENTS
(AIs)
(SERMs)
![Page 26: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/26.jpg)
HORMONAL AGENTS
(SERMs) (AIs)
![Page 27: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/27.jpg)
SYSTEMIC CHEMOTHERAPY
◦NEO-ADJUVANT CHEMOTHERAPY
◦ADJUVANT CHEMOTHERAPY
![Page 28: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/28.jpg)
Neoadjuvant
chemotherapy
![Page 29: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/29.jpg)
Adjuvant
chemotherapy
![Page 30: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/30.jpg)
![Page 31: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/31.jpg)
NCCN; FIRST LINE CHEMOTHERAPY BREAST CANCER HER2 NEGATIVE
![Page 32: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/32.jpg)
NCCN; FIRST LINE CHEMOTHERAPY BREAST CANCER HER2 NEGATIVE
![Page 33: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/33.jpg)
NCCN Guidelines
(2016)
Invasive Breast Cancer:
Systemic adjuvant
Chemotherapy:
Hormone receptor
negative and HER2
positive disease
![Page 34: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/34.jpg)
NCCN Guidelines
(2016)
Invasive Breast
Cancer:
HR negative and HER2
POSITIVE:
AC/TC + Trastuzumab or
Pertuzumab
![Page 35: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/35.jpg)
NCCN Guidelines
(2016)
Invasive Breast
Cancer:
Systemic therapy for HER2
positive recurrent or
metastatic Breast Cancer
Ado-trastuzumab
emtansine (T-DM1): highly
potent anti microtubule
agent
![Page 36: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/36.jpg)
NCCN; FIRST LINE CHEMOTHERAPY BREAST CANCER HER2 positive
![Page 37: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/37.jpg)
ANTI HER2 AGENTS:
![Page 38: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/38.jpg)
TRASTUZUMAB: Anti-Her2 extracellular domain
![Page 39: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/39.jpg)
PERTUZUMAB:
![Page 40: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/40.jpg)
Mechanisms of action from trastuzumab and pertuzumab
![Page 41: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/41.jpg)
T-DM1: Ado trastuzumab Emtansine
Antibody-drug conjugate for metastasis breast cancerHer2 positive, who previously received a trastuzumab.
![Page 42: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/42.jpg)
AVOIDABLE FOR
TREATMENT WITH
TRASTUZUMAB
Cardiotoxicity more
concurrent with
anthracycline agents
![Page 43: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/43.jpg)
Other systemic therapy: lapatinib
Oral dual tyrosine kinase inhibitor; HER2 AND EGFR
![Page 44: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/44.jpg)
LAPATINIB (TYKERB): oral chemotherapy, small-molecule, dual target agent.
![Page 45: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/45.jpg)
PALBOCICLIB: CDK 4/6 inhibitors
![Page 46: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/46.jpg)
PALBOCICLIB:
![Page 47: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/47.jpg)
EVEROLIMUS:
HR+: HORMONAL TREATMENT RESISTANCE,
PI3K MUTATION
![Page 48: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/48.jpg)
PEMBROLIZUMAB: IMMUNOTHERAPY (PD-L1)
![Page 49: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/49.jpg)
: OLAPARIB, a PARP inhibitor
![Page 50: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/50.jpg)
![Page 51: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/51.jpg)
![Page 52: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/52.jpg)
SUKSME
BREAST CANCER
![Page 53: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/53.jpg)
![Page 54: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/54.jpg)
![Page 55: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/55.jpg)
![Page 56: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/56.jpg)
![Page 57: TERAPI SISTEMIK KANKER PAYUDARA](https://reader031.vdocuments.mx/reader031/viewer/2022012423/617790d17796b849a4636ea3/html5/thumbnails/57.jpg)